The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Riociguat for Patients With Pulmonary Hypertension Caused by Systolic Left Ventricular Dysfunction: A Phase IIb Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Hemodynamic Study
Abstract
Background—: Pulmonary hypertension caused by systolic left ventricular dysfunction is associated with significant morbidity and mortality; however, no treatment is approved for this indication. We hypothesized that riociguat, a novel soluble guanylate cyclase stimulator, would have beneficial hemodynamic effects in patients with pulmonary hypertension caused by systolic left ventricular dysfunction. Methods and Results—: Overall, 201 patients with heart failure resulting from pulmonary hypertension caused by systolic left ventricular dysfunction were randomized to double-blind treatment with oral placebo or riociguat (0.5, 1, or 2 mg 3 times daily) for 16 weeks in 4 parallel arms. The primary outcome was the placebo-corrected change from baseline at week 16 in mean pulmonary artery pressure. Although the decrease in mean pulmonary artery pressure in the riociguat 2 mg group (−6.1±1.3 mm Hg; P <0.0001 versus baseline) was not significantly different from placebo ( P =0.10), cardiac index (0.4 L·min −1 ·m −2 ; 95% confidence interval, 0.2–0.5; P =0.0001) and stroke volume index (5.2 mL·m −2 ; 95% confidence interval, 2.0–8.4; P =0.0018) were significantly increased without changes in heart rate or systemic blood pressure compared with placebo. Both pulmonary (−46.6 dynes·s −1 ·cm −5 ; 95% confidence interval, –89.4 to –3.8; P =0.03) and systemic vascular resistance (−239.3 dynes·s −1 ·cm −5 ; 95% confidence interval, –363.4 to –115.3; P =0.0002) were significantly reduced with riociguat 2 mg. Riociguat reduced the Minnesota Living With Heart Failure score ( P =0.0002). Discontinuation of treatment was similar between treatment groups. Conclusions—: Although the primary end point of the study was not met, riociguat was well tolerated in patients with pulmonary hypertension caused by systolic left ventricular dysfunction and improved cardiac index and pulmonary and systemic vascular resistance. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT01065454.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction
Lam, C. S. P., Roger, V. L., Rodeheffer, R. J., Borlaug, B. A., Enders, F. T., & Redfield, M. M. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.11.051 · Cited by 1,341
Guidelines for the diagnosis and treatment of pulmonary hypertension
(2009) · European Respiratory Journal · doi:10.1183/09031936.00139009 · Cited by 1,300
Ghio, S., Gavazzi, A., Campana, C., Inserra, C., Klersy, C., Sebastiani, R., Arbustini, E., Recusani, F., & Tavazzi, L. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)01102-5 · Cited by 1,289
Self-citationCaliff, R. M., Adams, K. F., McKenna, W. J., Gheorghiade, M., Uretsky, B. F., McNulty, S. E., Darius, H., Schulman, K., Zannad, F., Handberg-Thurmond, E., et al. (1997) · American Heart Journal · doi:10.1016/s0002-8703(97)70105-4 · Cited by 665
Soluble Guanylate Cyclase as an Emerging Therapeutic Target in Cardiopulmonary Disease
Stasch, J.-P., Pacher, P., & Evgenov, O. V. (2011) · Circulation · doi:10.1161/circulationaha.110.981738 · Cited by 601
Michelakis, E., Tymchak, W., Lien, D., Webster, L., Hashimoto, K., & Archer, S. (2002) · Circulation · doi:10.1161/01.cir.0000016641.12984.dc · Cited by 577
Self-citationGuazzi, M., Vicenzi, M., Arena, R., & Guazzi, M. D. (2011) · Circulation · doi:10.1161/circulationaha.110.983866 · Cited by 545
Lewis, G. D., Shah, R., Shahzad, K., Camuso, J. M., Pappagianopoulos, P. P., Hung, J., Tawakol, A., Gerszten, R. E., Systrom, D. M., Bloch, K. D., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.716373 · Cited by 515
Self-citationVascular Endothelial Dysfunction and Mortality Risk in Patients With Chronic Heart Failure
Katz, S. D., Hryniewicz, K., Hriljac, I., Balidemaj, K., Dimayuga, C., Hudaihed, A., & Yasskiy, A. (2005) · Circulation · doi:10.1161/01.cir.0000153349.77489.cf · Cited by 410
Mulder, P., Richard, V., Derumeaux, G., Hogie, M., Henry, J. P., Lallemand, F., Compagnon, P., Macé, B., Comoy, E., Letac, B., et al. (1997) · Circulation · doi:10.1161/01.cir.96.6.1976 · Cited by 360
Cited by
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Galiè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Vonk Noordegraaf, A., Beghetti, M., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv317 · Cited by 6,931
Self-citationPhenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap
Shah, S. J., Kitzman, D. W., Borlaug, B. A., van Heerebeek, L., Zile, M. R., Kass, D. A., & Paulus, W. J. (2016) · Circulation · doi:10.1161/circulationaha.116.021884 · Cited by 1,003
Nitric oxide signalling in cardiovascular health and disease
Farah, C., Michel, L. Y. M., & Balligand, J.-L. (2018) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.224 · Cited by 779
Polsinelli, V. B., Sinha, A., & Shah, S. J. (2017) · Current Heart Failure Reports · doi:10.1007/s11897-017-0370-8 · Cited by 64
Role of sGC-dependent NO signalling and myocardial infarction risk
Wobst, J., Kessler, T., Dang, T. A., Erdmann, J., & Schunkert, H. (2015) · Journal of Molecular Medicine · doi:10.1007/s00109-015-1265-3 · Cited by 28
Metadata
- Authors
- Bonderman, D., Ghio, S., Felix, S. B., Ghofrani, H.-A., Michelakis, E., Mitrovic, V., Oudiz, R. J., Boateng, F., Scalise, A.-V., Roessig, L., & Semigran, M. J.
- Venue
- Circulation
- Published
- 2013-07-30
- Volume
- 128
- Issue
- 5
- Pages
- 502-511
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2028148874
- Cited by
- 326
- References
- 25
- FWCI
- 26.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Riociguat for Patients With Pulmonary Hypertension Caused by Systolic Left Ventricular Dysfunction: A Phase IIb Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Hemodynamic Study. https://app.cochat.ai/papers/10.1161/circulationaha.113.001458
- The paper
- Bonderman, D., Ghio, S., Felix, S. B., Ghofrani, H.-A., Michelakis, E., Mitrovic, V., Oudiz, R. J., Boateng, F., Scalise, A.-V., Roessig, L., & Semigran, M. J. (2013). Riociguat for Patients With Pulmonary Hypertension Caused by Systolic Left Ventricular Dysfunction: A Phase IIb Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Hemodynamic Study. Circulation. https://doi.org/10.1161/circulationaha.113.001458
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
